Difference between revisions of "Octreotide (Sandostatin)"
(updated content) |
m (updated also known as) |
||
| Line 15: | Line 15: | ||
==Also known as== | ==Also known as== | ||
| − | AO Ning, Longastatina, Octreotide, Octreotide Acetate, Octrestatin, Octride, Okeron, PEI XIN, Proclose, QI WEN, Samilstin, Sandostatin, Sandostatina, Sandostatine, YI PU BI Shang, YI PU Ning. | + | AO Ning, Longastatina, Octreotide, Octreotide immediate release, Octreotide IR, Octreotide Acetate, Octrestatin, Octride, Okeron, PEI XIN, Proclose, QI WEN, Samilstin, Sandostatin, Sandostatina, Sandostatine, YI PU BI Shang, YI PU Ning. |
==References== | ==References== | ||
Revision as of 05:44, 14 May 2013
General information
Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Octreotide (Sandostatin) patient drug information (Chemocare)[4]
- Octreotide (Sandostatin) patient drug information (UpToDate)[5]
Also known as
AO Ning, Longastatina, Octreotide, Octreotide immediate release, Octreotide IR, Octreotide Acetate, Octrestatin, Octride, Okeron, PEI XIN, Proclose, QI WEN, Samilstin, Sandostatin, Sandostatina, Sandostatine, YI PU BI Shang, YI PU Ning.